A NEW drug could dramatically slow the onset of memory loss for people with Alzheimer's disease.
Combined results from two trials showed that the drug, called solanezumab, slowed the speed of mental decline by a third in those with mild-to-moderate cases of the disease.
Despite enormous investment in experimental treatments for Alzheimer's, only a handful of drugs to tackle the disease have been approved.
These drugs are effective at alleviating some of the symptoms but they do not tackle the underlying cause of disease.
Eli Lilly, a pharmaceutical company, announced results for its new drug, which works to help clear the protein "plaques" thought to cause Alzheimer's.
Combined results from trials showed it slowed the pace of cognitive decline by 34pc over an 18-month period. Patients given the drug were compared with patients given a placebo.
The results were presented on Monday at a meeting of the American Neurological Association in Boston, Massachusetts.